Progenics Pharmaceuticals Inc Quick Ratio (PGNX) starting from the first quarter 2020 to first quarter 2019, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Progenics Pharmaceuticals Inc  (PGNX)

Progenics Pharmaceuticals Inc's Quick Ratio

PGNX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the first quarter 2020, Quick Ratio deteriorated to 1.6 a new company low.

Within Major Pharmaceutical Preparations industry 354 other companies have achieved higher Quick Ratio than Progenics Pharmaceuticals Inc in first quarter 2020. While Quick Ratio total ranking in the first quarter 2020 has deteriorated compared to the prior quarter from 846 to 1464.

Explain Quick Ratio?
How much Cash & cash equivalents PGNX´s has?
What are PGNX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PGNX Quick Ratio (Mar 31 2020)
Q1		 (Dec 31 2019)
Q4		 (Sep 30 2019)
Q3		 (Jun 30 2019)
Q2		 (Mar 31 2019)
Q1
Y / Y Current Liabilities Change -23.09 % -8.43 % 18.65 % 56.03 % 68.63 %
Y / Y Cash & cash equivalent Change -73.05 % -69.46 % -57.11 % -4.71 % 27.61 %
Quick Ratio MRQ 1.6 1.96 3.3 3.69 4.56
PGNX's Total Ranking # 1464 # 846 # 628 # 839 # 585
Seq. Current Liabilities Change -13.91 % 9.69 % -14.96 % -4.23 % 2.5 %
Seq. Cash & cash equivalent Change -29.77 % -34.8 % -23.97 % -22.6 % -20.41 %



Quick Ratio first quarter 2020 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 355
Healthcare Sector # 591
Overall Market # 1464


Quick Ratio Statistics
High Average Low
22.96 8.98 1.6
(Mar 31 2014)   (Mar 31 2020)




Financial Statements
Progenics Pharmaceuticals Inc's Current Liabilities $ 18 Millions Visit PGNX's Balance sheet
Progenics Pharmaceuticals Inc's Cash & cash equivalent $ 30 Millions Visit PGNX's Balance sheet
Source of PGNX's Sales Visit PGNX's Sales by Geography


Cumulative Progenics Pharmaceuticals Inc's Quick Ratio

PGNX's Quick Ratio for the trailling 12 Months

PGNX Quick Ratio

 (Mar 31 2020)
12 Months		 (Dec 31 2019)
12 Months		 (Sep 30 2019)
12 Months		 (Jun 30 2019)
12 Months		 (Mar 31 2019)
12 Months
Y / Y Current Liabilities TTM Growth 4.85 % 27.77 % 43.4 % 46.52 % 28.85 %
Y / Y Cash & cash equivalent TTM Growth -54.61 % -34.99 % -4.65 % 32.62 % 25.19 %
Quick Ratio TTM 2.68 3.42 4.4 5.55 6.18
Total Ranking TTM # 4709 # 4638 # 454 # 311 # 4416
Seq. Current Liabilities TTM Growth -6.3 % -2.2 % 3.54 % 10.5 % 14.19 %
Seq. Cash & cash equivalent TTM Growth -26.6 % -24.11 % -17.8 % -0.86 % 5.12 %

Quick ratio ranking by company, industry and sector >> Back to PGNX Financial Strength Comparisons >> Go to Compare PGNX Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in PGNX's Current Liabilities to $18.48 millions, cumulative Quick Ratio to 2.68 below the PGNX average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 490 other companies have achieved higher Quick Ratio than Progenics Pharmaceuticals Inc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2019 from 4638 to 4709.

Explain Quick Ratio?
How much Cash & cash equivalents PGNX´s has?
What are PGNX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 491
Healthcare Sector # 936
Within the Market # 4709


trailing twelve months Quick Ratio Statistics
High Average Low
19.81 9.1 2.6
(Mar 31 2015)   (Mar 31 2020)




Companies with similar Quick Ratio in the quarter ending Mar 31 2020, within Major Pharmaceutical Preparations Industry Quick RatioMar 31 2020 MRQ Cash & cash equivalentMar 31 2020 MRQ Current Liabilities
Proqr Therapeutics N v   4.38 $ 84.939  Millions$ 19.403  Millions
Optinose Inc   4.34 $ 148.475  Millions$ 34.225  Millions
Palvella Therapeutics Inc   4.24 $ 86.764  Millions$ 20.483  Millions
Jazz Pharmaceuticals Plc  4.20 $ 1,683.204  Millions$ 400.610  Millions
China Health Industries Holdings Inc   4.19 $ 36.594  Millions$ 8.733  Millions
Orgenesis Inc   4.13 $ 107.069  Millions$ 25.910  Millions
Amarin Corp Plcuk  4.04 $ 546.145  Millions$ 135.308  Millions
Cue Biopharma Inc   4.03 $ 48.730  Millions$ 12.090  Millions
Cormedix Inc   4.00 $ 23.208  Millions$ 5.804  Millions
Rezolute Inc   3.99 $ 14.068  Millions$ 3.530  Millions
Pacira Biosciences inc   3.97 $ 318.464  Millions$ 80.313  Millions
Acer Therapeutics Inc   3.94 $ 7.007  Millions$ 1.780  Millions
Celularity Inc   3.92 $ 0.505  Millions$ 0.129  Millions
Spero Therapeutics Inc   3.91 $ 88.841  Millions$ 22.741  Millions
Chemomab Therapeutics Ltd   3.87 $ 14.009  Millions$ 3.616  Millions
Alnylam Pharmaceuticals Inc   3.85 $ 1,304.125  Millions$ 338.791  Millions
Molecular Templates Inc   3.84 $ 104.988  Millions$ 27.309  Millions
Lipocine Inc   3.84 $ 15.583  Millions$ 4.060  Millions
Scorpius Holdings inc   3.81 $ 26.445  Millions$ 6.937  Millions
Zentalis Pharmaceuticals Inc   3.76 $ 63.650  Millions$ 16.939  Millions
Igc Pharma Inc   3.73 $ 7.258  Millions$ 1.946  Millions
Amicus Therapeutics inc   3.69 $ 338.873  Millions$ 91.714  Millions
Tvardi Therapeutics Inc   3.69 $ 120.196  Millions$ 32.603  Millions
Heron Therapeutics Inc   3.68 $ 356.346  Millions$ 96.765  Millions
Intercept Pharmaceuticals inc   3.66 $ 549.036  Millions$ 149.968  Millions
Rockwell Medical inc   3.66 $ 48.856  Millions$ 13.357  Millions
Purple Biotech Ltd  3.63 $ 11.247  Millions$ 3.098  Millions
Siga Technologies Inc  3.61 $ 77.377  Millions$ 21.425  Millions
Summit Therapeutics Inc   3.61 $ 55.296  Millions$ 15.320  Millions
Moleculin Biotech Inc   3.60 $ 11.649  Millions$ 3.235  Millions

Date modified: 2026-09-08T15:09:55+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.